Haemostatic factors and atherogenesis

Atherosclerosis

Volumn 124, Issue 2, 1996, Pages 137-143

  Smith, Elspeth B ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Atherogenesis; Fibrin; Plasminogen activator inhibitor; Plasminogen activators; Thrombin

Indexed keywords

FIBRIN; FIBRINOGEN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; THROMBIN;

ATHEROGENESIS; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; REVIEW;

EID: 0030564980     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(96)05837-6     Document Type: Review

References (80)

1. [1] Rokitansky C. A Manual of Pathological Anatomy, Vol IV, part II, chapter 3 - Abnormal Conditions of the Arteries. London, Sydenham Society, 1952.
2. [2] Duguid JB. Thrombosis as a factor in the pathogenesis of coronary atherosclerosis. J Pathol Bacteriol 1946;58:207.
3. [3] Duguid JB. Thrombosis as a factor in the pathogenesis of aortic atherosclerosis. J Path Bact 1948;60:57.
4. [4] Loscalzo J. The relation between atherosclerosis and thrombosis. Circulation 1992;86 suppl III:III-95.
5. [5] Tankaka K, Sueishi K. Biology of disease: the coagulation and fibrinolysis systems and atherosclerosis. Lab Invest 1993;69:5.
6. [6] Smith EB. Fibrinogen and atherosclerosis. Wien Klin Wochenschr 1993;105:417.
7. [7] Smith EB, Thompson WD. Fibrin as a factor in atherogenesis. Thromb Res 1994;73:1.
8. [8] Rabbani LeR E, Loscalzo J. Recent observations on the role of hemostatic determinants in the development on the role of hemostatic determinants in the development of the atherothrombotic plaque. Atherosclerosis 1994;105:1.
9. [9] Lassila R, Peltonen S, Lepantalo M et al. Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. Atheroscler Thromb 1993;13:1738.
10. [10] Kwaan HC. The biologic role of components of the plasminogen-plasmin system. Prog Cardiovasc Diseases 1992;34:309.
11. [11] Vassalli J-D, Sappino A-P, Belin D. The plasminogen activator/plasminogen system. J Clin Invest 1991;88:1067.
12. [12] Key NS. Scratching the surface: endothelium as a regulator of thrombosis, fibrinoysis and inflammation. J Lab Clin Med 1992;120:184.
13. [13] Miles LA, Levin EO, Plescia J, Collen D, Plow EF. Plasminogen receptors, urokinase receptors and their modulation on human endothelial cells. Blood 1988;72:628.
14. [14] Kirchheimer JC, Remold HG. Functional characteristics of receptor-bound urokinase on human monocytes: catalytic efficiency and susceptibility to inactivation by plasminogen activator inhibitors. Blood 1989;74:1396.
15. [15] Hajjar KA, Hamel NM. Identification and characterisation of human endothelial cell binding sites for tissue plasminogen activator and urokinase. J Biol Chem 1990;265:2908.
16. [16] Blasi F, Conese M, Moller LB et al. The urokinase receptor: structure, regulation and inhibitor mediated internalisation. Fibrinolysis 1994;8-suppl 1:182.
17. [17] Cubellis MV, Andreasen P, Ragno P et al. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc Nat Acad Sci USA 1989;86:4828.
18. [18] Ellis V, Wun T-C, Behrendt N, Ronne E, Dano K. Inhibition of receptor-bound urokinase by plasminogen activator inhibitors. J Biol Chem 1990;265:9904.
19. [19] Estreicher A, Muhlhauser J, Carpentier J-L, Orci L, Vassalli J-D. The receptor for urokinase-type plasminogen activator polarises expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme-inhibitor complexes. J Cell Biol 1990;111:783.
20. [20] Grimsley PO, Normyle JF, Brandt RA et al. Urokinase binding and catabolism by HEP G2 cells is plasminogen activator inhibitor-1 dependent, analogous to interactions of tissue-type plasminogen activator with these cells. Thromb Res 1995;79:353.
21. [21] Felez J, Miles LA, Plescia J, Plow EF. Regulation of plasminogen receptor expression on human monocytes and monocytoid cell lines. J Cell Biol 1990;111:1673.
22. [22] Liaw L, Schwartz SM. Comparison of gene expression in bovine aortic endothelium in vivo versus in vitro. Arterioscler Thromb 1993;13:985.
23. [23] Lupu F, Bergonzelli CE, Heim DA et al. Localisation and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993;13:1090.
24. [24] Padro T, Emeis JJ, Steins M, Schmid KW, Kienast J. Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vasc Biol 1995;15:893.
25. [25] Raghunath PN, Tomaszewski JE, Brady ST et al. Plasminogen activator system in human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1995;15:1432.
26. [26] Lupu F, Heim DA, Bachmann F et al. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995;15:1444.
27. [27] Carmeliet P, Collen D. Evaluation of the plasminogen/ plasmin system in transgenic mice. Fibrinolysis 1994;8 suppl 1:269.
28. [28] Carmeliet P, Mulligan RC, Collen D. Transgenic animals as tools for the study of fibrinoysis in vivo. J Intern Med 1994;236:455.
29. [29] Carmeliet P, Collen D. Role of the plasminogen/plasmin system in the vessel wall. In: Woodford FP, Davignon J and Sniderman A (eds). Atherosclerosis X. Elsevier: Amsterdam 1995;45.
30. [30] Simon DI, Ezratty AM, Francis SA, Rennke H, Loscalzo J. Fibrin(ogen) is internalised and degraded by activated human monocytoid cells via Mac-1 (CD 11b/CD18): a non-plasmin fibrinolytic pathway. Blood 1993;82:2414.
31. [31] Simon DI, Ezratty AM, Loscalzo J. The fibrin(ogen)olytic proberties of cathepsin D. Biochemistry 1994;33:6555.
32. [32] Brunner G, Preissner KT. Pericellular enzymic hydrolysis: implications for the regulation of cell proliferation in the vessel wall and the bone marrow. Blood Coag Fibrinol 1994;5:625.
33. [33] Mimuro J, Schleef RR, Loskutoff DJ. Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active Type 1 plasminogen activator inhibitor. Blood 1987;70:721.
34. [34] Seiffert D, Wagner NN, Loskutoff DJ. Serum-derived vitronectin influences the pericellular distribution of type-1 plasminogen activator inhibitor. J Cell Biol 1990;111:1283.
35. [35] Smith EB, Keen GA, Grant A, Stirk C. Fate of fibrinogen in human aterial intima. Ateriosclerosis 1990;10:263.
36. [36] Nieuwenhuizen W. Sites in fibrin involved in the acceleration of plasminogen activation by t-PA. Possible role of fibrin polymerisation. Thromb Res 1994;75:343.
37. [37] Bach-Gansmo ET, Halvorsen S, Godal HC, Skjonsberg OH. Degradation of the α-chain of fibrin by human neutrophil elastase reduces the stimulating effect of fibrin on plasminogen activation. Thromb Res 1994;75:307.
38. [38] Collet J-P, Mishal Z, Vasse M et al. Pharmacological approaches of fibrin gel architecture modulation and thrombus degradation: its implication in atherogenesis and thromboembolism disease. Thromb Res 1994;75:353.
39. [39] Anglescano E. Overview on fibrinolysis - plasminogen activation pathways on fibrin and cell surfaces. Chem Phys Lipids 1994;67:353.
40. [40] Carr ME, Alving BM. Effect of fibrin structure on plasmin-mediated dissolution of plasma clots. Blood Coag Fibrinol 1995;6:567.
41. [41] Fenton JW. Thrombin functions and antithrombotic intervention. Thromb Haemost 1995;74:493.
42. [42] Levin EG, Marzec U, Anderson J, Harker LA. Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. J Clin Invest 1984;74:1988.
43. [43] Van Hinsbergh VWM, Sprengers ED, Kooistra T. Effect of thrombin on the production of plasminogen activators and PA inhibitor-1 by human foreskin microvascular endothelial cells. Thromb Haemost 1987;57:148.
44. [44] Shatos MA, Orfeo T, Doherty JM et al. α-Thrombin stimulates urokinase production and DNA synthesis in cultured human cerebral microvascular endothelial cells. Arterioscler Thromb Vasc Biol 1995;15:903.
45. [45] Heaton JH, Dame MK, Gelehrter TD. Thrombin induction of plasminogen activator inhibitor mRNA in human umbilical vein endothelial cells in culture. J Lab Clin Med 1992;120:222.
46. [46] Al-Azhary DB, Wojta J, Binder BR. Fibrinolytic system of cultured rabbit aortic endothelial cells. Thromb Res 1994;75:559.
47. [47] Malik AB, Fenton JW. Thrombin-mediated increase in vascular endothelial permeability. Semin Thromb Hemost 1992;18:193.
48. [48] DeMichele MA, Minnear FL. Modulation of vascular endothelial permeability by thrombin. Semin Thromb Hemost 1992;18:287.
49. [49] Kiely J-M, Cybulski MI, Luscinskas FW, Gimbrone MA. Immunoselective targeting of an anti-thrombin agent to the surface of cytokine-activated vascular endothelial cells. Arterioscler Thromb Vasc Biol 1995;15:1211.
50. [50] Parkinson JF, Bang NU, Garcia JGN. Recombinant human thrombomodulin attenuates human endothelial cell activation by human thrombin. Arterioscler Thromb 1993;13:1119.
51. [51] Clowes AW, Clowes MM, Au YPT, Reidy MA, Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 1990;67:61.
52. [52] Noda-Heiny H, Fujii S, Sobel BE. Induction of vascular smooth muscle cell expression of plasminogen activator inhibitor-1 by thrombin. Circ Res 1993;72:36.
53. [53] Wenzel UO, Fouqueray B, Grandaliano G et al. Thrombin regulates expression of monocyte chemoaltractant protein-1 in vascular smooth muscle cells. Circ Res 1995;77:503.
54. [54] McNamara CA, Sarembock IJ, Gimple LW et al. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest 1993;91:94.
55. [55] Hedin U, Frebelius S, Sanchez J, Dryjski M, Swedenborg J. Antithrombin III inhibits thrombin-induced proliferation in human arterial smooth muscle cells. Arterioscler Thromb 1994;14:254.
56. [56] Bachhuber BG, Sarembock IJ, Gimple LW, McNamara CA, Owens GK. Thrombin-induced mitogenesis in cultured aortic smooth muscle cells requires prolonged thrombin exposure. Am J Physiol 1995;268(Cell Physiol 37):C1141.
57. [57] Chaikof EL, Caban R, Yan CN, Rao GN, Runge MS. Growth-related responses in arterial smooth muscle cells are arrested by thrombin receptor antisense sequences. J Biol Chem 1995;270:7431.
58. [58] Bar-Shavit R, Benezra M, Eldort A et al. Thrombin immobilised to extracellular matrix is a potent mitogen for vascular smooth muscle cells: nonenzymatic mode of action. Cell Regul 1990;1:453.
59. [59] Dawes KE, Gray AJ, Laurent GJ. Thrombin stimulates fibroblast chemotaxis and replication. Eur J Cell Biol 1993;61:126.
60. [60] de Munk GAW, Groeneveld E, Rijken DC. Acceleration of the thrombin inactivation of single chain urokinase-type plasminogen activator by thrombomodulin. J Clin Invest 1991;88:1680.
61. [61] Haskel EJ, Eisenberg PR, Abendschein DR. Inhibition of concomitant thrombin-mediated fibrin formation enhances clot lysis in whole blood. Blood Coag Fibrinol 1993;4:7.
62. [62] Gast A, Tschopp TB, Schmid G, Hilpert K, Ackermann J. Inhibition of clot-bound and free (fluid phase) thrombin by a novel synthetic thrombin inhibitor (Ro46-6240), rocombinant hirudin and heparin in human plasma. Blood Coag Fibrinol 1994;5:879.
63. [63] Salatti JA, Fenton J, Anton P, Sakariassen KS. α-Thrombin bound to extracellular endothelial matrix induces pronounced fibrin deposition and platelet thrombus growth in flowing non-anticoagulated human blood. Blood Coag Fibrinol 1994;5:561.
64. [64] Stirk CM, Kochhar A, Smith EB, Thompson WD. Presence of growth-stimulating fibrin degradation products containing fragment E in human atherosclorotic plaques. Atherosclerosis 1993;103:159.
65. [65] Gray AJ, Bishop JE, Reeves JT, Laurent GJ. Aα and Bβ chains of fibrinogen stimulate proliferation of human fibroblasts. J Cell Sci 1993;104:409.
66. [66] Wilcox JN. Thrombin and other potential mechanisms underlying restenosis. Circulation 1991;84:432.
67. [67] Schwartz RS, Holmes DR, Topol EJ. The restenosis paradigm revisted: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992;20:1284.
68. [68] Smith EB. Fibrinogen, fibrin and the arterial wall. Eur Heart J 1995;16(suppl A)11.
69. [69] Smith EB, Crosbie L, Carey S. Prothrombin-related antigens in human aortic intima. Semin Thromb Hemost (In press).
70. [70] Nelken NA, Soifer SJ, O'Keefe J et al. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 1992;90:1614.
71. [71] Zacharski LR, Memoli VA, Morain WD, Schlaeppi J-M, Rousseau SM. Cellular localisation of enzymatically active thrombin in intact human tissues by hirudin binding. Thromb Haemost 1995;73:793.
72. [72] Carney DH, Mann R, Redin WR et al. Enhancement of incisional wound healing and neovascularisation in normal rats by thrombin and synthetic thrombin receptor-activating peptides. J Clin Invest 1992;89:1469.
73. [73] Lefkovits J. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994;90:1522.
74. [74] Lumsden AB, Kelly AB, Schneider PA et al. Lasting safe interruption of endarterectomy thrombosis by transiently infused antithrombin peptide. D-Phe-Pro-Arg CH2CL in baboons. Blood 1993;81:1762.
75. [75] Meyer BJ, Badimon JJ, Mailhac A et al. Inhibition of growth of thrombus on fresh mural thrombus. Circulation 1994;90:2432.
76. [76] Wilcox JN, Rodriguez J, Subramanian R. Chracterisation of thrombin receptor expression during vascular lesion formation. Circ Res 1994;75:1029.
77. [77] Libby P, Sukhova G, Kranzhofer R, Tanaka H. Cellular activation in restenosis following angioplasty. In: Atherosclerosis X, Woodford FP, Davignon J and Sniderman A (eds). Elsevier, 1995;690.
78. [78] Seruys PW, Herrman J-P R, Simon R et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995;333:757.
79. [79] Bittl JA, Strony J, Brinker JA et al. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or post-infarction angina. N Engl J Med 1995;333:764.
80. [80] Schwartz SM. Serum-derived growth factor is thrombin? J Clin Invest 1993;91:4.